Complement receptor 2 targeted complement modulators

Details Complement receptor 2 targeted complement modulators Complement receptor 2 targeted complement modulators

2011-08-30

2011-08-30

Wen, Sharon (Department: 1644)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C536S023100, C536S023400

Reexamination Certificate

active

08007804

ABSTRACT:
Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

REFERENCES:
patent: 4883784 (1989-11-01), Kaneko
patent: 5212071 (1993-05-01), Fearon et al.
patent: 5260203 (1993-11-01), Ladner et al.
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5472939 (1995-12-01), Fearon et al.
patent: 5679546 (1997-10-01), Ko et al.
patent: 5851528 (1998-12-01), Ko et al.
patent: 5949562 (1999-09-01), Kubota et al.
patent: 5949961 (1999-09-01), Sharman
patent: 5981481 (1999-11-01), Fearon et al.
patent: 6140472 (2000-10-01), Rosengard et al.
patent: 6248365 (2001-06-01), Römisch et al.
patent: 6291239 (2001-09-01), Prodinger et al.
patent: 6432679 (2002-08-01), Mond et al.
patent: 6458360 (2002-10-01), Fearon et al.
patent: 6503947 (2003-01-01), Lipton et al.
patent: 6521450 (2003-02-01), Atkinson et al.
patent: 6820011 (2004-11-01), Chen et al.
patent: 6897290 (2005-05-01), Atkinson et al.
patent: 7759304 (2010-07-01), Gilkeson et al.
patent: 2002/0103346 (2002-08-01), Vogel et al.
patent: 2005/0265995 (2005-12-01), Tomlinson et al.
patent: 2006/0002944 (2006-01-01), Ashkenazi et al.
patent: 2006/0014681 (2006-01-01), Chen et al.
patent: 2006/0178308 (2006-08-01), Schwaeble et al.
patent: 2006/0263819 (2006-11-01), Hageman et al.
patent: 2007/0224197 (2007-09-01), Chen et al.
patent: 2008/0221011 (2008-09-01), Gilkeson et al.
patent: 0 402 226 (1990-12-01), None
patent: 5-507197 (1993-10-01), None
patent: 9-502985 (1997-03-01), None
patent: WO-91/16437 (1991-10-01), None
patent: WO-98/07835 (1998-02-01), None
patent: WO-98/07835 (1998-02-01), None
patent: WO-2004/103288 (2004-12-01), None
patent: WO-2004/103288 (2004-12-01), None
patent: WO-2007/035857 (2007-03-01), None
patent: WO-2007/035857 (2007-03-01), None
Abrahmsen, L. et al. (Apr. 30, 1991). “Engineering Subtilisin and Its Substrates for Efficient Ligation of Peptide Bonds in Aqueous Solution,”Biochemistry30(17):4151-4159.
Ahearn, J.M. et al. (Mar. 1996). “Disruption of theCr2Locus Results in a Reduction in B-1a Cells and in an Impaired B Cell Response to T-Dependent Antigen,”Immunity4(3):251-262.
Amsterdam, E.A. et al. (Jan. 1995). “Limitation of Reperfusion Injury by a Monoclonal Antibody to C5a During Myocardial Infarction in Pigs,”Am. J. Physiol. 268(1):H448-H457.
Andrews, B.S. et al. (Oct. 1, 1978). “Spontaneous Murine Lupus-like Syndromes. Clinical and Immunopathological Manifestations in Several Strains,”J. Exp. Med. 148(4):1198-1215.
Aslam, M. et al. (Jun. 22, 2001). “Folded-Back Solution Structure of Monomeric Factor H of Human Complement by Synchrotron X-ray and Neutron Scattering, Analytical Ultracentrifugation and Constrained Molecular Modelling,”J. Mol. Biol. 309(5):1117-1138.
Aubry, J-P. et al. (Aug. 6, 1992). “CD21 is a Ligand for CD23 and Regulates IgE Production,”Nature358(6386):505-507.
Bagshawe, K.D. et al. (1988). “A Cytotoxic Agent can be Generated Selectively at Cancer Sites,”Br. J. Cancer58:700-703.
Bagshawe, K.D. (1989). “Towards Generating Cytotoxic Agents at Cancer Sites,”Br. J. Cancer60:275-281.
Baranyi, L. et al. (Aug. 1994). “Cell-Surface Bound Complement Regulatory Activity is Necessary for the in vivo Survival of KDH-8 Rat Hepatoma,”Immunology82(4):522-528.
Barlow, P.N. et al. (Jul. 5, 1993). “Solution Structure of a Pair of Complement Modules by Nuclear Magnetic Resonance,”J. Mol. Biol. 232:268-284.
Battelli, M.G. et al. (1992). “T Lymphocyte Killing by a Xanthine-Oxidase-Containing Immunotoxin,”Cancer Immunol. Immunother. 35:421-425.
Bergelson, J.M. et al. (Jun. 21, 1994). “Decay-Accelerating Factor (CD55), A Glycosylphosphatidylinositol-Anchored Complement Regulatory Protein, Is a Receptor for Several Echoviruses,”Proc. Natl. Acad. Sci. USA91(13):6245-6249.
Brown, V.I. et al. (Jul./Aug. 1991). “Molecular and Cellular Mechanisms of Receptor-Mediated Endocytosis,”DNA and Cell Biology10(6):399-409.
Cambier, J-C. (May 1997). “Signalling Processes in Haematopoietic Cells: Positive and Negative Signal Co-operativity in the Immune System: The BCR, FcγRIIB, CR2 Paradigm,”Biochem. Soc. Trans. 25(2):441-445.
Caragine, T.A. et al. (Feb. 15, 2002). “A Tumor-Expressed Inhibitor of the Early but not Late Complement Lytic Pathway Enhances Tumor Growth in a Rat Model of Human Breast Cancer,”Cancer Res. 62(4):1110-1115.
Carel, J.C. et al. (Jul. 25, 1990). “Structural Requirements for C3d,g/Epstein-Barr Virus Receptor (CR2/CD21) Ligand Binding, Internalization, and Viral Infection,”J. Biol. Chem. 265(21):12293-12299.
Carroll, M.C. (1998). “The Role of Complement and Complement Receptors in Induction and Regulation of Immunity,”Annu. Rev. Immunol. 16:545-568.
Carroll, M.C. (2000). “The Role of Complement in B Cell Activation and Tolerance”Advances in Immunology, Dixon, F.J. ed., Academic Press, Inc., 74:61-88.
Carter, R.H. et al. (Apr. 3, 1992). “CD19: Lowering the Threshold for Antigen Receptor Stimulation of B Lymphocytes,”Science256:105-107.
Casasnovas, J.M. et al. (1999). “Crystal Structure of Two CD46 Domains Reveals an Extended Measles Virus-Binding Surface,”EMBO J. 18(11):2911-2922.
Chen, S-H. et al. (Apr. 12, 1994). “Gene Therapy for Brain Tumors: Regression of Experimental Gliomas by Adenovirus-Mediated Gene Transfer in vivo,”Proc. Natl. Acad. Sci. USA91(8):3054-3057.
Chen, S. et al. (Jun. 1, 2000). “CD59 Expressed on a Tumor Cell Surface Modulates Decay-Accelerating Factor Expression and Enhances Tumor Growth in a Rat Model of Human Neuroblastoma,”Cancer Res. 60(11):3013-3018.
Christiansen, D. et al. (Mar. 1996). “A Functional Analysis of Recombinant Soluble CD46 in vivo and a Comparison with Recombinant Soluble Forms of CD55 and CD35 in vitro,”European Journal of Immunology26(3):578-585.
Clemenza, L. et al. (Oct. 1, 2000). “Structure-Guided Identification of C3d Residues Essential for Its Binding to Complement Receptor 2 (CD21),”J. Immunol. 165(7):3839-3848.
Davies, A. et al. (Sep. 1, 1989). “CD59, an Ly-6-Like Protein Expressed in Human Lymphoid Cells, Regulates the Action of the Complement Membrane Attack Complex on Homologous Cells,”Journal of Experimental Medicine170(3):637-654.
de Córdoba, S.R. et al. (2004). “The Human Complement Factor H: Functional Roles, Genetic Variations and Disease Associations,”Molecular Immunology41:355-367.
Dempsey, P.W. et al. (Jan. 19, 1996). “C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity,”Science271:348-350.
Dev, S.B. et al. (Jan. 1994). “Electrochemotherapy—A Novel Method of Cancer Treatment,”Cancer Treat. Rev. 20(1):105-115.
Diefenbach, R.J. et al. (Mar. 1, 1995). “Mutation of Residues in the C3dg Region of Human Complement Component C3 Corresponding to a Proposed Binding Site for Complement Receptor Type 2 (CR2, CD21) Does Not Abolish Binding of iC3b or C3dg to CR2,”J. Immunol. 154(5):2303-2320.
Dierich, M.P. et al. (Nov. 1988). “Structural and Functional Relationships Among Receptors and Regulators of the Complement System,”Mol. Immunol. 25(11):1043-1051.
Dörig, R.E. et al. (Oct. 22, 1993). “The Human CD46 Molecule Is a Receptor for Measles Virus (Edmonston Strain),”Cell75(2):295-305.
Duits, A.J. et al. (1991). “Selective Enhancement of Leu-Cam Expression by Interleukin 6 During Differentiation of Human Promonocytic U937 Cells,

Affiliated with

Also associated with

Rating

Complement receptor 2 targeted complement modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Complement receptor 2 targeted complement modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Complement receptor 2 targeted complement modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2740670